Dark

BIIB
Biogen Inc. Common Stock
stock NASDAQ

At Close

Mar 13, 2026 3:59:59 PM EDT

181.51USD-1.833%(-3.39)1,092,302

0.00Bid 0.00Ask 0.00Spread

Pre-market

Mar 12, 2026 8:46:30 AM EDT

189.00USD+2.217%(+4.10)0

After-hours

Mar 13, 2026 4:07:30 PM EDT

181.53USD+0.011%(+0.02)23,979

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

07:34AM EST Biogen Announces Nancy Leaming And Brian Posner To Retire From Board RTTNews

07:30AM EST Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogens Board of Directors, effective at the time of the Companys 2022 annual meeting of stockholders. GlobeNewswire Inc

Jan 28, 2022

10:01AM EST Hearing Dealreporter Reports Aurinia Pharma Said To Be On Biogen's Takeover Radar Benzinga

08:21AM EST The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron Benzinga

Jan 27, 2022

09:44PM EST Samsung Biologics agreed to buy Biogen Inc.'s (BIIB) equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion, the companies said in a statement. RTTNews

07:27PM EST Samsung Biologics Reached Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis for Up to $2.3B Benzinga

07:34AM EST Biogen And Eisai Co. Announce Update On The Phase 4 ENVISION Confirmatory Study Of ADUHELM Benzinga

07:30AM EST Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM(aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimers disease, including details of the studys goal for diverse enrollment and primary endpoint. GlobeNewswire Inc

Jan 24, 2022

07:39AM EST 10 Biggest Price Target Changes For Monday Benzinga

04:28AM EST SVB Leerink Maintains Outperform on Biogen, Lowers Price Target to $300 Benzinga

Jan 20, 2022

09:52AM EST Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $244 Benzinga

Jan 18, 2022

09:06AM EST Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $360 Benzinga

06:47AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

06:11AM EST HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $270 Benzinga

Jan 13, 2022

02:17PM EST 'With its Alzheimer's drug in turmoil, Biogen eyes a list of potential acquisitions' -STAT News Report Benzinga

11:50AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022 Benzinga

11:45AM EST 10 Biggest Price Target Changes For Thursday Benzinga

11:44AM EST Guggenheim Downgrades Biogen to Neutral, Lowers Price Target to $202 Benzinga

Jan 12, 2022

01:54PM EST This Is What Whales Are Betting On Biogen Benzinga

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 12, 2022 Benzinga

09:12AM EST Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jan. 12, 2022: BIIB, AMD, RBLX, LYFT, IMMX Benzinga

08:59AM EST Wedbush Maintains Neutral on Biogen, Lowers Price Target to $195 Benzinga

08:41AM EST Mizuho Maintains Neutral on Biogen, Lowers Price Target to $207 Benzinga

08:30AM EST The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award Benzinga

07:45AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:14AM EST Needham Maintains Buy on Biogen, Lowers Price Target to $292 Benzinga

05:33AM EST Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $216 Benzinga

Jan 11, 2022

05:07PM EST STAT News Reporter Adam Feuerstein Posts Response From Biogen On CMS Draft Decision; Co Says Will 'Continue to urge CMS to align Medicare coverage for class of amyloid-directed therapies' Benzinga

04:23PM EST UPDATE: CMS Listing For Alzheimer's Shows Trials That Include Beta Amyloid Positron Emission Tomograph Scan Must Also Meet Requirement Of Coverage With Evidence Development Benzinga

04:22PM EST 'Medicare plans to restrict access to controversial, pricey Alzheimer's drug Aduhelm to patients in clinical trials' -STAT Benzinga

04:22PM EST UPDATE: Centers For Medicare, Medicaid Services Listing On Alzheimer's Treatment Shows CMS 'proposes to cover FDA approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease under Coverage with Evidence Development' Benzinga

04:21PM EST Biogen Shares Down After Hours Following US Centers For Medicare Listing For 'Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease' Benzinga

04:15PM EST What 20 Analyst Ratings Have To Say About Biogen Benzinga

09:23AM EST TLSA: SPMS Update; Second Patient Gains Access Benzinga

06:49AM EST Needham Maintains Buy on Biogen, Lowers Price Target to $328 Benzinga

Jan 10, 2022

10:01AM EST Biogen Executive Says Rolling Submission For Accelerated Approval Of Second Alzheimer's Drug Lecanemab Ongoing, Expected To Be Completed In H1 2022 Benzinga

09:45AM EST US Health & Human Secretary Says Given 50% Price Drop Of Biogen's Aduhelm, There Is Compelling Basis For Centers For Medicare Services To Reexamine Previous Recommendation On Aduhelm Benzinga

07:01AM EST - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response GlobeNewswire Inc

Jan 8, 2022

02:57PM EST Barron's Latest Picks And Pans: Visa, AT&T, Biogen, Robinhood And More Benzinga

Jan 6, 2022

10:16AM EST Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $363 Benzinga

Jan 4, 2022

08:07AM EST Biogen Licenses Global Rights To Develop, Commercialize RTTNews

07:35AM EST Biogen Exercises Option To Obtain From Ionis A Worldwide License To Develop BIIB115/ION306 RTTNews

07:34AM EST Biogen Exercises Option With Ionis To Develop And Commercialize Investigational ASO For SMA Benzinga

07:34AM EST -- BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervals -- Biogen paid Ionis a $60 million one-time upfront payment GlobeNewswire Inc

07:30AM EST Biogen Exercises Option with Ionis to Develop and Commercialize Investigational PR Newswire

Jan 3, 2022

06:19AM EST Medicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT Benzinga

Dec 30, 2021

11:15AM EST What Are Whales Doing With Biogen Benzinga

10:29AM EST Shares of Boston-based drugmaker Biogen Inc. (BIIB) are down more than 7 percent on Thursday's trading after Samsung BioLogics denied news reports that it was discussing takeover plans with Biogen, which would value the drugmaker at around $42 billon. RTTNews

08:39AM EST Benzinga Pro's Top 5 Stocks To Watch For Thursday, Dec. 30, 2021: BIIB, DIDI, FTFT, BYSI, PIXY Benzinga

04:31AM EST Samsung Biologics Denied That Parent Samsung Group Is Looking to Buy U.S. Drug Company Biogen Benzinga

Dec 29, 2021

10:56PM EST Samsung Group Reportedly In Talks To Buy Biogen RTTNews

02:17PM EST UPDATE: KED Reports Biogen 'approached Samsung to sell its shares, which could be valued at more than 50 trillion won ($42 billion)' Benzinga

02:15PM EST Biogen Shares Spike Following Korea Economic Daily Global Edition Report 'Samsung Group in negotiations to buy Biogen' Benzinga

Dec 27, 2021

09:53AM EST Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today Benzinga

Dec 23, 2021

06:30PM EST INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK PR Newswire

08:09AM EST B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $275 Benzinga

Dec 22, 2021

10:29AM EST Expert Ratings For Biogen Benzinga

08:12AM EST Biogen: Japan's NDC Seeks Additional Data On Application RTTNews

07:51AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

07:44AM EST Biogen:Japan Regulator To Continue Deliberations On Application For Marketing Approval Of Aducanumab RTTNews

07:33AM EST Biogen Announces Japan's First Committee On New Drugs Of The Pharmaceutical Affairs And Food Sanitation Council Seeks Additional Data; Aducanumab Remains Under Review Benzinga

07:30AM EST Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $350 Benzinga

07:30AM EST Japans First Committee on New Drugs of The GlobeNewswire Inc

Dec 21, 2021

10:34AM EST Analyst Ratings For Biogen Benzinga

10:01AM EST JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $276 Benzinga

06:51AM EST Baird Maintains Neutral on Biogen, Lowers Price Target to $258 Benzinga

Dec 20, 2021

10:02AM EST Biogen shares were trading higher. The company announced it will reduce the wholesale acquisition cost of ADUHELM 100 mg/mL injection for intravenous use in the US by approximately 50%. Also, SVB Leerink maintained an Outperform rating on the stock. Benzinga

07:45AM EST Biogen Inc. (BIIB) said it will reduce the wholesale acquisition cost of ADUHELM 100 mg/mL injection for intravenous use in the U.S. by approximately 50%, effective January 1, 2022. For a patient of average weight, the yearly cost at the maintenance dose will be $28,200. RTTNews

07:29AM EST Biogen Reduces Price For ADUHELM For Alzheimer's Disease By About 50% RTTNews

07:19AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:04AM EST Biogen Reduces the Price of its ADUHELM for Patients with Early Alzheimer's Disease Benzinga

07:00AM EST Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200. GlobeNewswire Inc

04:49AM EST SVB Leerink Maintains Outperform on Biogen, Lowers Price Target to $325 Benzinga

Dec 17, 2021

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

07:38AM EST Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted by European Medicines Agency or EMA for the company's Alzheimer's drug aducanumab. RTTNews

06:52AM EST Biogen And Eisai Announce EU Regulatory Committee Has Given Negative Opinion For Aducanumab RTTNews

06:44AM EST Biogen Says 'to seek re-examination following CHMP negative opinion for aducanumab' Benzinga

06:44AM EST Update on Regulatory Submission for Aducanumab in the European Union GlobeNewswire Inc

06:10AM EST Biogen's Alzheimer's Drug Receives Negative Recommendation In European Union Benzinga

Dec 16, 2021

12:12PM EST Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026 Benzinga

08:20AM EST The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street Benzinga

07:05AM EST Biogen Announces Update On The Phase 4 Confirmatory Study Of ADUHELM Benzinga

07:00AM EST Biogen Inc.(Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an important update on the continuing progress of the Phase 4 post-marketing confirmatory study of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in Alzheimers disease. GlobeNewswire Inc

Dec 14, 2021

07:00AM EST -- Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology -- Biogen to gain exclusive rights to TheraPanacea technology in neuroscience GlobeNewswire Inc

Dec 13, 2021

01:29PM EST Senator Wyden Says U.S. Should Nix Medicare Premium Rise Linked To Aduhelm Benzinga

Dec 10, 2021

10:37AM EST Amid Shaky Launch Of Aduhelm, Biogen Mulls Substantial Layoffs: STAT News Report Benzinga

Dec 9, 2021

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:47PM EST Wells Fargo Initiates Coverage On Biogen with Equal-Weight Rating, Announces Price Target of $250 Benzinga

Dec 8, 2021

08:19AM EST The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom Benzinga

07:59AM EST 'Did you know Biogen $BIIB put together a plan to acquire Neurocrine Biosciences $NBIX in 2019? Well, now you do! We take you inside the thwarted M&A plan, and how it was seen as a vote of no confidence in Vounatsos.' -STAT's Adam Feuerstein Benzinga

07:03AM EST Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress. RTTNews

06:38AM EST Sage : Data From Clinical Program Further Shows Efficacy & Safety Profile Of Zuranolone For Treatment Of MDD RTTNews

06:32AM EST Sage Therapeutics and Biogen Announce New Analyses From LANDSCAPE Clinical Development Program Of Zuranolone In MDD Presented At The American College Of Neuropsychopharmacology Congress Benzinga

06:30AM EST Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress Business Wire

Dec 6, 2021

11:13AM EST Where Biogen Stands With Analysts Benzinga

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 Benzinga

06:27AM EST Goldman Sachs Initiates Coverage On Biogen with Neutral Rating, Announces Price Target of $271 Benzinga

Dec 1, 2021

08:44AM EST Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced a positive, one-year Zuranolone 50 mg data in the ongoing open-label SHORELINE study in Patients with major depressive disorder or MDD. RTTNews

08:41AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case Benzinga

08:36AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case Benzinga

07:21AM EST Healthcare company Viatris Inc. (VTRS) announced Wednesday that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. RTTNews

07:02AM EST Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen' Tecfidera Patent RTTNews

06:39AM EST Sage Therapeutics Announce Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder RTTNews

06:31AM EST Sage Therapeutics And Biogen Announce One-Year Zuranolone 50 mg Data In Ongoing Open-Label SHORELINE Study Benzinga

06:30AM EST Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD Business Wire

Nov 30, 2021

04:58PM EST Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg Benzinga

04:58PM EST 'Biogen loses bid to revive patent on Tecfidera MS drug' -Bloomberg Report Benzinga

Nov 21, 2021

03:05PM EST The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week Benzinga

Nov 19, 2021

12:00PM EST Where Biogen Stands With Analysts Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

08:39AM EST RBC Capital Maintains Sector Perform on Biogen, Lowers Price Target to $277 Benzinga

07:39AM EST Biogen Gives Tecfidera Update For European Medicines Agency Committee for Medicinal Products for Human Use: Says CHMP Concludes That Totality Of Available Data Cannot Establish Candidate Exerts Clinically Relevant Contribution Benzinga

05:33AM EST BMO Capital Initiates Coverage On Biogen with Outperform Rating, Announces Price Target of $315 Benzinga

Nov 18, 2021

10:23AM EST UPDATE: 'Insurers Balk at Paying for Biogen's $56,000-a-Year Alzheimer's Treatment' -Recent Bloomberg Report Benzinga

Nov 17, 2021

03:17PM EST Shares of Biogen Inc. (BIIB) are down on Wednesday after the advisory committee of the European Medicines Agency recommended a "negative trend vote" for the company's Alzheimer's therapy drug Aducanumab. RTTNews

07:35AM EST Biogen Says Following An Oral Explanation Held At The November Meeting Of The CHMP, Co. Received Negative Trend Vote On Aducanumab Marketing Authorization Application Benzinga

07:30AM EST Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimers disease by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). GlobeNewswire Inc

Nov 16, 2021

01:20PM EST Europe OKs Biogen's Vumerity For Multiple Sclerosis Benzinga

09:22AM EST Biogen Says The European Commission Grants Marketing Authorization For VUMERITY (diroximel fumarate) As Oral Treatment For Relapsing-Remitting Multiple Sclerosis Benzinga

09:20AM EST The European Commission Grants Marketing Authorization for GlobeNewswire Inc

08:31AM EST The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment Benzinga

Nov 15, 2021

07:30AM EST Biogen Sets Industry Record with Recognition on Dow Jones GlobeNewswire Inc

Nov 12, 2021

01:20PM EST President Biden Nominates Robert Califf As New FDA Commissioner: Report Benzinga

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

Nov 11, 2021

05:10PM EST New Phase 3 Data Show Positive Correlation Between GlobeNewswire Inc

12:58PM EST Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial Benzinga

12:01PM EST Biogen Partner Eisai Highlights Introduction Of Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial At Alzheimer's Disease Conference Benzinga

12:00PM EST Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Conference PR Newswire

11:21AM EST Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase PR Newswire

11:20AM EST Biogen Says Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference Benzinga

08:03AM EST The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts Benzinga

Nov 10, 2021

03:02PM EST Biogen Offers Updated Assessment Of Ole Phase Showed Treatment With Lecanemab Resulted In Reduction Of Brain Amyloid Levels In As Early As 3 Months Benzinga

02:58PM EST Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD) Conference PR Newswire

12:37PM EST Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

10:59AM EST UPDATE: RBC Capital Maintains Sector Perform Rating, $295 Price Target On Biogen Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 3, 2021

09:16AM EDT Biogen Highlights Late-Breaking Presentations, Added New Presentations For Clinical Trials On Alzheimer's Disease Meeting Nov. 9-12 Benzinga

07:30AM EDT Biogen Announces Late Breakers and Additional New Data GlobeNewswire Inc

Oct 26, 2021

12:36PM EDT Expert Ratings For Biogen Benzinga

09:17AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:55AM EDT Mizuho Maintains Neutral on Biogen, Lowers Price Target to $270 Benzinga

Oct 21, 2021

12:56PM EDT Analyst Ratings For Biogen Benzinga

12:12PM EDT Cowen & Co. Maintains Outperform on Biogen, Lowers Price Target to $375 Benzinga

12:12PM EDT Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $440 Benzinga

12:11PM EDT 10 Biggest Price Target Changes For Thursday Benzinga

12:11PM EDT RBC Capital Maintains Sector Perform on Biogen, Lowers Price Target to $295 Benzinga

12:11PM EDT Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $390 Benzinga

12:11PM EDT Needham Maintains Buy on Biogen, Lowers Price Target to $386 Benzinga

Oct 20, 2021

10:34AM EDT Abbot Labs and Biogen Outshine Novavax in the Health Care Sector Benzinga

08:16AM EDT The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review Benzinga

08:10AM EDT Biogen Says The Healthcare System Remains A Significant Bottleneck To Alzheimer's Drug Launch Benzinga

07:32AM EDT While reporting third-quarter results on Wednesday, Biogen Inc. (BIIB) increased its full year 2021 financial guidance. The updated financial guidance assumes minimal ADUHELM revenue in 2021, ramping thereafter. Also, the company expects it will utilize a portion of the remaining share repurchase authorization of $2.8 billion through the end of 2021. RTTNews

07:18AM EDT UPDATE: Biogen Raises FY21 Adj. EPS Guidance Form $17.50-$19.00 To $18.85-$19.35, Raised Sales Guidance From $10.65B-$10.85B To $10.8B-$10.9B Benzinga

07:16AM EDT Biogen Inc. (BIIB) released earnings for third quarter that decreased from last year. RTTNews

07:10AM EDT Biogen Sees FY21 Sales $10.8B-$10.9B vs $10.76B Est. Benzinga

07:09AM EDT Biogen Sees FY21 Adj. EPS $18.85-$19.35 vs $18.61 Est. Benzinga

07:07AM EDT Biogen Q3 EPS $2.22 Vs $4.46 Last Year RTTNews

07:07AM EDT Biogen Q3 EPS $4.77 Beats $4.11 Estimate, Sales $2.78B Beat $2.67B Estimate Benzinga

03:44AM EDT Earnings Scheduled For October 20, 2021 Benzinga

Oct 19, 2021

12:08PM EDT Expert Ratings For Biogen Benzinga

10:13AM EDT Earnings Outlook For Biogen Benzinga

06:35AM EDT Sage Therapeutics, Biogen Plan To Submit NDA For Zuranolone To FDA In H2 Of 2022 RTTNews

06:34AM EDT Sage Therapeutics and Biogen Announcd Plans to Submit NDA for Zuranolone to FDA in H@ 2022 with Rolling Submission Expected to Start in Early 2022 Benzinga

06:31AM EDT Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022 Business Wire

06:04AM EDT Needham Maintains Buy on Biogen, Lowers Price Target to $398 Benzinga

Oct 18, 2021

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

Oct 17, 2021

05:09PM EDT Biogen Announced in Phase 3 Valor Study, the Primary Endpoint as Measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale Did Not Reach Statistical Significance Benzinga

04:20PM EDT Biogen Announces Topline Results from the Tofersen Phase 3 GlobeNewswire Inc

Oct 15, 2021

12:15PM EDT Analyst Ratings For Biogen Benzinga

09:22AM EDT Stifel Maintains Buy on Biogen, Lowers Price Target to $344 Benzinga

09:17AM EDT Cantor Fitzgerald Maintains Neutral on Biogen, Lowers Price Target to $327 Benzinga

Oct 14, 2021

04:11PM EDT Biogen Highlights Topline Results From Tofersen Phase 3 Study, Its Open Label Extension In Superoxide Dismutase 1 Amyotrophic Lateral Sclerosis At American Neurological Association Meeting Benzinga

04:06PM EDT Topline Results from Tofersen Phase 3 Study and its Open Label GlobeNewswire Inc

Oct 13, 2021

06:05AM EDT New Data at ECTRIMS 2021 Highlight Biogens Focus GlobeNewswire Inc

06:04AM EDT Biogen Inc. Highlights Presentation Of MS PATHS Data At ECTRIMS 2021 Oct. 13-15 Benzinga

06:02AM EDT New MS PATHS Data at ECTRIMS 2021 Confirm GlobeNewswire Inc

Oct 12, 2021

12:22PM EDT Where Biogen Stands With Analysts Benzinga

08:09AM EDT Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $447 Benzinga

08:04AM EDT 'Biogen - Noted y'day, EMA CHMP agenda for the October meeting doesn't include a discussion of Aduhelm. That puts off the review decision to the November meeting, at earliest' -Tweet From STAT News Reporter Adam Feuerstein Benzinga

Oct 8, 2021

12:11PM EDT Analyst Ratings For Biogen Benzinga

09:03AM EDT Jefferies Maintains Buy on Biogen, Lowers Price Target to $400 Benzinga

06:45AM EDT Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $290 Benzinga

Oct 5, 2021

10:45AM EDT Rising Oil Prices and Yields Makes Market Navigation More Complex Benzinga

Oct 4, 2021

06:32AM EDT Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress Benzinga

Sep 29, 2021

01:21PM EDT Analyst Ratings For Biogen Benzinga

07:24AM EDT RBC Capital Maintains Sector Perform on Biogen, Lowers Price Target to $326 Benzinga

Sep 28, 2021

09:19AM EDT Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug Benzinga

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 27, 2021

07:30PM EDT Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway PR Newswire

Sep 23, 2021

05:04PM EDT Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst Benzinga

12:42PM EDT Where Biogen Stands With Analysts Benzinga

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

09:36AM EDT Cowen Says Medicaid, CMS Advising All States They Must Cover Biogen/Eiasi's Aduhelm Underexisting Participation Benzinga

09:34AM EDT Hearing Cowen Says Medicaid, CMS Advising All States They Must Cover Biogen/Eiasi's Aduhelm Underexisting Participation Benzinga

09:09AM EDT Thinking About Buying Stock Or Options In Tesla, Ballard Power, Bloom Energy Or Biogen? Benzinga

04:39AM EDT Needham Initiates Coverage On Biogen with Buy Rating, Announces Price Target of $400 Benzinga

Sep 22, 2021

04:52PM EDT Biogen Considers Drastic Cost-Cutting Measures As RTTNews

Sep 21, 2021

11:57AM EDT Apple Working On iPhone Features To Detect Depression, Cognitive Decline: Report Benzinga

10:41AM EDT Biogen CEO Says Working Diligently To Address Near-Term Challenges With Launch Of Alzheimer's Drug Aduhelm Benzinga

08:37AM EDT Biogen To Host Virtual Investor R&D Day Tuesday, Sept. 21, 2021 Benzinga

08:30AM EDT Biogen R&D Day to Provide Overview of Diversified Pipeline and GlobeNewswire Inc

Sep 20, 2021

08:13AM EDT Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) announced Monday that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). RTTNews

07:44AM EDT FDA Approves BYOOVIZ, A Proposed Biosimilar To Lucentis RTTNews

07:34AM EDT FDA Approves Samsung Bioepis And Biogen's BYOOVIZ, LUCENTIS Biosimilar Benzinga

07:30AM EDT -- BYOOVIZ becomes the first ophthalmology biosimilar to gain FDA approval in the United States GlobeNewswire Inc

Sep 17, 2021

09:37AM EDT Biogen : CHMP Recommends VUMERITY For Approval In EU As Treatment For RRMS RTTNews

09:10AM EDT Biogen Says CHMP Recommends VUMERITY For Approval In EU As Treatment For Relapsing-Remitting Multiple Sclerosis Benzinga

09:09AM EDT CHMP Recommends VUMERITY(diroximel GlobeNewswire Inc

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

01:22PM EDT Expert Ratings For Biogen Benzinga

01:20PM EDT Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate Benzinga

10:21AM EDT ALZN: An Elemental Approach to Alzheimer's Disease Benzinga

08:41AM EDT UBS Maintains Buy on Biogen, Lowers Price Target to $442 Benzinga

08:37AM EDT Biogen Inc. (BIIB) announced positive results from its Phase 2 CONVEY study of vixotrigine or BIIB074, a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy. RTTNews

07:35AM EDT Biogen Announces Positive Topline Results From Phase 2 CONVEY Study In Small Fiber Neuropathy RTTNews

07:32AM EDT Biogen Announces Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy; Co. Reports 'The CONVEY study 200 mg twice daily arm met its primary endpoint while the 350 mg twice daily arm did not meet the primary endpoint' Benzinga

07:30AM EDT Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from its Phase 2 CONVEY study of vixotrigine(BIIB074), anon-opioidinvestigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN). GlobeNewswire Inc

Sep 15, 2021

03:08PM EDT Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know Benzinga

07:32AM EDT Biogen Plans To Initiate Phase 3b Study Evaluating Potential Benefit Of A Higher Dose Of Nusinersen In Patients Previously Treated With Evrysdi Benzinga

07:30AM EDT Biogen Plans to Initiate Phase 3b Study Evaluating Potential GlobeNewswire Inc

Sep 12, 2021

04:04PM EDT The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Benzinga

Sep 10, 2021

07:36PM EDT 'Biogen trials for Alzheimer's drug excluded much of the targeted patient pool, study finds' -STAT Benzinga

Sep 9, 2021

03:42PM EDT Biotech giant Biogen Inc. (BIIB) on Thursday admitted that the launch of its controversial Alzheimer's drug Aduhelm "was slower than we initially anticipated." RTTNews

02:32PM EDT Why Biogen Shares Are Falling Benzinga

09:45AM EDT '#BIIB execs are speaking at an investor conference right now, remarking in more public detail than ever before the issues that are negatively impacting the commercial launch of Aduhelm.' -STAT News Reporter Tweet Benzinga

Sep 2, 2021

11:04AM EDT Lawmakers Cite 'Apparent Anomalies' In Aduhelm Approval Process Benzinga

Aug 31, 2021

12:36PM EDT Expert Ratings For Biogen Benzinga

Aug 30, 2021

03:51PM EDT Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free Benzinga

Aug 21, 2021

11:27AM EDT Expert Ratings For Biogen Benzinga

Aug 20, 2021

04:37PM EDT White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg Benzinga

Aug 17, 2021

01:14PM EDT Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's Benzinga

12:05PM EDT 'Eisai-Biogen Alzheimer's drug set for use at 300-plus US hospitals: exec' -Nikkei Benzinga

Aug 16, 2021

04:34PM EDT 13F From Warren Buffett's Berkshire Hathaway Shows New Stake In Organon, Raised Stake In Kroger, Liquidated Stakes In Axalta Coating Systems, Biogen Benzinga

01:26PM EDT Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization Benzinga

Aug 12, 2021

07:53AM EDT Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs Benzinga

Aug 4, 2021

12:59PM EDT Health & Human Services Will Not Assess Scientific Appropriateness Of Biogen's Alzheimer Candidate Approval Benzinga

12:57PM EDT HHS to Review Fda's Accelerated Approval After Biogen Approval Benzinga

Aug 2, 2021

01:18PM EDT Analyst Ratings for Biogen Benzinga

08:43AM EDT Biogen Inc. (BIIB) said results from phase 3b NOVA Study showed that every six-week natalizumab IV administration provides a high level of efficacy in controlling Multiple Sclerosis disease activity in patients who switched from the approved every four-week dosing regimen. RTTNews

08:18AM EDT Mizuho Maintains Neutral on Biogen, Raises Price Target to $300 Benzinga

07:40AM EDT Biogen Announces Results From Phase 3b NOVA Study Evaluating Natalizumab In Relapsing-Remitting Multiple Sclerosis RTTNews

07:32AM EDT Biogen Announces Results From Phase 3b NOVA Study Evaluating Every Six-Week Dosing With Natalizumab In Relapsing-Remitting Multiple Sclerosis Benzinga

07:30AM EDT Biogen Announces Results from Phase 3b NOVA Study Evaluating Every GlobeNewswire Inc

Jul 30, 2021

12:31PM EDT Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World Benzinga

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

04:35PM EDT Eisai, Biogen Highlight Late-Breaking Alzheimer's Association Int'l. Conference Presentation Explores Potential Clinical Effects Of Lecanemab Benzinga

04:31PM EDT Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of PR Newswire

12:01PM EDT Where Biogen Stands With Analysts Benzinga